Ranbaxy buys Romanian generics drugs company
The deal will combine the strengths of the two generics companies and will allow Ranbaxy to leverage its expanded base in the rapidly growing Romanian pharmaceutical market, across
The US Food and Drug Administration (FDA) is set to review Kowa Pharmaceuticals America’s new drug application (NDA) for K-911, an investigational once-daily eye drop aimed at reducing intraocular pressure (IOP) in open-angle glaucoma (OAG) or ocular hypertension (OHT) patients.